Blog

DEEP RESEARCH · ILDONG PHARM/YUNOVIA

Ildong’s P-CAB Candidate: Padoprazan Transfer and Commercialization Strategy

An analysis of ID120040002’s move to Yunovia, the Daewon licensing deal, and the Korean P-CAB competitive landscape.

Date: 2025-11-26 · Pharma/licensing analysis · Naver Blog

You are responsible for your own investment decisions. This material is research and is not a recommendation to buy or sell.

0. Bottom line first

I view the transfer of ID120040002, or padoprazan, and the Daewon licensing deal as a strategic reshuffling rather than a simple asset sale. It links Ildong’s balance-sheet repair, Yunovia’s specialization as an R&D company, and Daewon’s need to fill a P-CAB portfolio gap.

Padoprazan value migrationReducing parent burden and securing a commercialization partner
IldongSeparates R&D burden
YunoviaOwns ID120040002 and global rights
DaewonKorean development and sales rights
MarketLate-entry P-CAB competition
The key is whether phase 3 data and Daewon’s sales network can offset latecomer risk.

1. Why the restructuring happened

Official fact: The source says Ildong had been spending close to 20% of revenue on R&D, with annual R&D expense above KRW 100 billion in the early 2020s, creating persistent operating-loss pressure.

Official fact: In November 2023, Ildong spun off its R&D unit into Yunovia. Metabolic and digestive-disease pipelines including ID120040002, ID110521156, and ID119031166 were gathered under Yunovia.

Interpretation: The structure shields the parent company’s earnings from R&D burden and lets Yunovia seek outside funding and licensing deals as a focused drug-development company.

2. The Daewon licensing deal

Official fact: Yunovia signed a co-development and licensing agreement with Daewon Pharmaceutical in May 2024. Daewon is developing the asset under the project name DW4421 and secured exclusive Korean approval, manufacturing, and sales rights.

Official fact: The source says Daewon will lead phase 2 and phase 3 development and bear clinical costs, while Yunovia keeps global rights outside Korea and off-brand domestic rights. Yunovia may receive upfront payment, development milestones, and royalties after commercialization.

Interpretation: Yunovia transfers much of the domestic commercialization risk to Daewon while gaining cash flow and data for global licensing. Daewon fills its lack of an internal P-CAB candidate and can combine the asset with its respiratory and internal-medicine sales network.

3. Padoprazan product profile

Mechanism

P-CAB

It inhibits gastric acid secretion by competitively binding with potassium ions at H+/K+-ATPase.

Convenience

Less meal dependence

Unlike PPIs, activity against active and inactive pumps supports the case for dosing regardless of meals.

Differentiation

pH holding time

Early data cited in the source shows about 90% of 24 hours above pH 4 and about 60% above pH 6.

Official fact: The phase 2 trial involved 147 ERD patients, and the source says padoprazan showed superior mucosal healing versus control with tolerability confirmed.

Official fact: Phase 3 is designed for 327 patients across 22 hospitals using randomized, double-blind, active-comparator design, targeting treatment of erosive reflux disease.

ItemK-CABFexuclueJaqboPadoprazan
DeveloperHK inno.NDaewoongJeil/OnconicIldong/Yunovia·Daewon
Launch2019202220242026-2027 expected
Half-lifeAbout 4-5hAbout 9hAbout 6-10hData pending
StrengthBroad indications, orally disintegrating tabletLong half-life, nocturnal acid controlPrice competitiveness, dual mechanismPotential 90% pH>4 holding time
PositionClear No. 1Strong No. 2New entrant, fast growthLate entrant in phase 3

4. Competition and commercialization

Official fact: The source says K-CAB cumulative prescriptions exceeded KRW 1.5 trillion, Fexuclue surpassed KRW 100 billion annual sales within two years, and Jaqbo exceeded KRW 10 billion cumulative prescriptions within six months of its October 2024 launch.

Interpretation: Padoprazan is likely the fourth or fifth domestic P-CAB, so late-entry risk is high. Daewon’s respiratory and internal-medicine network must create targeted demand, including GERD patients with chronic cough or laryngitis symptoms.

5. Financial implications

  • Upfront and milestone payments from Daewon can slow Yunovia’s cash burn and support next-pipeline development.
  • Daewon’s phase 3 data can support Yunovia’s future licensing discussions in China, the U.S., Europe, and other markets.
  • The source says Ildong returned to operating profit from 2024 after Yunovia’s spin-off effect.
  • The value of Ildong’s 100% stake in Yunovia and future off-brand rights are key monitoring points.

6. Monitoring points

  • Watch whether phase 3 data on pH holding time, nocturnal symptom relief, and healing rate is compelling versus competitors.
  • Check whether Daewon can absorb latecomer P-CAB marketing cost while maintaining profitability.
  • Additional global licensing deals by Yunovia will determine the asset’s upside beyond Korea.

Sources

Naver original